Active Ingredient: Eptinezumab
Dosage Form: Injection
Strength: 60 mg per 1.2 mL
Quantity: Single dose vial (1.2 mL)

 

Medical Uses

• Migraine Prevention:
  • Primary Use: Ngenla is indicated for the prevention of both episodic and chronic migraines in adults. It works by blocking the CGRP protein, which is involved in the development and maintenance of migraines.
  • Administration: The recommended dose is a single 60 mg injection administered intravenously every 3 months. This dosing schedule aims to decrease the frequency and severity of migraine attacks.

 

Usage in Sports and Bodybuilding

Why Athletes Might Use Ngenla:

• Migraine Management: Athletes who experience frequent migraines may use Ngenla to manage their condition effectively. Reducing the number and intensity of migraines helps in maintaining a consistent training regimen and overall performance.

 

How Athletes Use Ngenla:

• Dosage: For migraine prevention, a dose of 60 mg is administered intravenously every 3 months. This higher dose can provide more extended relief compared to lower doses, depending on individual response.
• Administration: The injection is given by a healthcare professional in a clinical setting. Athletes should follow medical advice to ensure correct administration and to monitor for any side effects.

 

Storage Conditions:

• Temperature: Store in a refrigerator at 2°C to 8°C (36°F to 46°F).
• Light: Protect from light by keeping in the original carton.
• Moisture: Store in a dry place; do not freeze.
• Preparation: Inspect the solution before use. Do not use if it appears cloudy or contains particles.
• Expiry: Adhere to the expiration date on the packaging. Discard any unused portions.

 

Precautions and Side Effects

Potential Side Effects:

• Common Reactions: Possible side effects include injection site reactions (pain, redness, or swelling) and mild flu-like symptoms.
• Serious Reactions: Severe allergic reactions or hypersensitivity to eptinezumab, though rare, can occur. Immediate medical attention is required if signs of severe allergic reactions are observed.

 

Medical Warnings:

• Pre-existing Conditions: Individuals with a history of severe allergic reactions to eptinezumab or any component of the medication should avoid use.
• Pregnancy and Nursing: The safety of Ngenla during pregnancy or breastfeeding has not been established. It should be used only if the potential benefits outweigh the risks. Consult a healthcare provider before use if pregnant or breastfeeding.

 

Consultation:

• Medical Supervision: Use Ngenla under the supervision of a qualified healthcare provider. Regular follow-ups are essential to assess the effectiveness and manage any adverse effects.

 

Conclusion

Ngenla 60 mg/1.2 mL is a specialized injectable medication designed for migraine prevention. By inhibiting CGRP, it helps in reducing the frequency and severity of migraine episodes. Administered intravenously every 3 months, it provides extended relief for chronic and episodic migraines.

 

For more information or to schedule an appointment, please contact us at info@staminapharma.com.